Department of Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Department of Laboratory, Affiliated Hospital of Jilin Medical College, No 81 HuaShan Road, Jilin, 132013, China.
World J Surg Oncol. 2021 Aug 11;19(1):239. doi: 10.1186/s12957-021-02347-7.
miR-92b is a carcinogenic miRNA that has great potential as a biomarker for disease prognosis, diagnosis, and treatment in the clinic. It is of great significance to analyse the relationship between miR-92b and the clinicopathological characteristics of cancer patients. This paper aimed to investigate the expression levels and clinical values of miR-92b-3p in breast cancer (BC).
Altogether, 112 female BC patients who were treated in our hospital were included as a study group, and 108 healthy women who came to our hospital for physical examinations were included as a control group. miR-92b-3p expression in the serum of subjects in both groups was detected by fluorescence quantitative PCR (RT-PCR) to analyse the correlation of this miRNA with the patients' pathological features and prognoses. The diagnostic value of miR-92b-3p expression for BC was analysed by plotting a receiver operating characteristic (ROC) curve.
miR-92b-3p expression was remarkably higher in the study group (P < 0.05), and its area under the curve (AUC) for detecting BC was 0.88. The expression was correlated with the tumour size, degree of differentiation, TNM staging, and lymphatic metastasis (P < 0.05). miR-92b-3p was significantly positively correlated with the TNM staging (r = 0.40, P < 0.05), was significantly negatively correlated with the degree of differentiation of the breast cancer cells (r = - 0.35, P < 0.05), and was significantly positively correlated with the expression of carbohydrate antigen 125 (CA125) (r = 0.39, P < 0.05). The overall survival rate (OSR) of the 99 patients who had follow-up was 73.74%. The survival status was remarkably better in the low expression group (P < 0.05). miR-92b-3p expression was remarkably higher in the death group (P < 0.05). The AUC of miR-92b-3p alone in the death and survival groups was 0.76.
miR-92b-3p expression obviously rises in the serum of BC patients and is closely related to the clinical staging, degree of differentiation, and CA125 in BC, so the detection of this miRNA is of great significance to the diagnosis and prognostic evaluation of BC. This miRNA can be used as a potential biomarker for the diagnosis and prognosis of the disease.
miR-92b 是一种致癌 miRNA，作为疾病预后、诊断和临床治疗的生物标志物具有很大的潜力。分析 miR-92b 与癌症患者临床病理特征之间的关系具有重要意义。本研究旨在探讨 miR-92b-3p 在乳腺癌（BC）中的表达水平及临床价值。
选取我院收治的 112 例女性 BC 患者作为研究组，另选取同期来我院体检的 108 例健康女性作为对照组。采用荧光定量 PCR（RT-PCR）检测两组受试者血清中 miR-92b-3p 的表达情况，分析该 miRNA 与患者病理特征及预后的相关性。通过绘制受试者工作特征（ROC）曲线分析 miR-92b-3p 表达对 BC 的诊断价值。
研究组 miR-92b-3p 表达明显高于对照组（P<0.05），其检测 BC 的曲线下面积（AUC）为 0.88。miR-92b-3p 的表达与肿瘤大小、分化程度、TNM 分期及淋巴转移有关（P<0.05）。miR-92b-3p 与 TNM 分期呈显著正相关（r=0.40，P<0.05），与乳腺癌细胞分化程度呈显著负相关（r=-0.35，P<0.05），与糖链抗原 125（CA125）的表达呈显著正相关（r=0.39，P<0.05）。99 例有随访结果的患者总体生存率（OSR）为 73.74%。低表达组的生存状况明显更好（P<0.05）。死亡组 miR-92b-3p 表达明显更高（P<0.05）。miR-92b-3p 单独在死亡组和生存组的 AUC 为 0.76。
BC 患者血清中 miR-92b-3p 表达明显升高，与 BC 的临床分期、分化程度及 CA125 密切相关，因此检测该 miRNA 对 BC 的诊断和预后评估具有重要意义。该 miRNA 可作为疾病诊断和预后的潜在生物标志物。
